Perspective Therapeutics’ [212Pb]VMT-α-NET Shows 39% Response, 76% PFS at 5.0 mCi
Perspective Therapeutics’ Phase 1/2a trial of [212Pb]VMT-α-NET in neuroendocrine tumors delivered a 39% response rate at the 5.0 mCi dose and 76% progression-free survival among 25 evaluable patients. No dose-limiting toxicities emerged among 56 patients, the 6.0 mCi cohort cleared toxicity criteria, and enrollment continues ahead of 2026 regulatory engagement.
1. Interim Efficacy Results
At the 2026 ASCO Gastrointestinal Cancers Symposium, Perspective Therapeutics presented interim data from its Phase 1/2a [212Pb]VMT-α-NET trial in neuroendocrine tumors, reporting a 39% objective response rate among 23 patients at the 5.0 mCi dose and 76% progression-free survival across 25 evaluable patients.
2. Safety and Tolerability
Safety evaluation across 56 participants showed no dose-limiting toxicities, treatment-related discontinuations, or clinically significant myelosuppression, underscoring a favorable tolerability profile at assessed dose levels.
3. Higher-Dose Cohort Progression
The 6.0 mCi cohort cleared dose-limiting toxicity assessment, prompting enrollment of additional patients at the higher dose, with initial efficacy data pending and regulatory engagement planned for 2026 to support a registrational trial.